Therapy of ankylosing spondylitis – a review. Part I: Conventional medical treatment and surgical therapy
Authors:
- 1 April 2005
- journal article
- review article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 34 (2) , 97-108
Abstract
The main outcome parameters in AS and other SpA are pain, disease activity, function, spinal mobility, and structural progression. There are several treatment options, which differ, depending on the localization and severity of the manifestation and the degree of structural changes already present. There is a basic role for physiotherapy to improve and maintain spinal mobility and function and prevent handicap. The basis for drug therapy in AS is NSAIDs, which may also have an influence on structural progression. DMARDs are mainly used in cases with peripheral arthritis. Corticosteroids have a clear role for intra-articular therapy, while the role for systemic use is, in contrast to RA, mainly reserved for subgroups. It is largely unclear whether long-term spinal progression can be prevented by conventional drug therapy. Treatment with biologics such as anti-TNF-alpha therapy is discussed in Part 2 of this review. To be published in the next issue of the Scandinavian Journal of Rheumatology. Surgical treatment of the spine is indicated in cases of severe instability pain, in cases of deformity endangering the patient in daily life by the limited range of vision, and in patients with neurological deficiency. AS-specific problems are spinal fractures and atlantoaxial instability, which need careful management including surgery. Joint replacement therapy is established and beneficial for AS-disturbed joints of the hip and knee.Keywords
This publication has 108 references indexed in Scilit:
- Mucosal damage induced by preferential COX-1 and COX-2 inhibitors: Role of prostaglandins and inflammatory responseLife Sciences, 2004
- Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us?Rheumatic Disease Clinics of North America, 2003
- Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) dataRheumatology, 2003
- Neue Aspekte in Behandlung und Prophylaxe gastrointestinaler Nebenwirkungen durch nicht-steroidale Antiphlogistika (NSA)Zeitschrift für Rheumatologie, 1999
- Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathyRheumatology, 1999
- Health-related quality of life in ankylosing spondylitis: A survey of 175 patientsArthritis & Rheumatism, 1999
- Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trialRheumatology, 1999
- PROGNOSIS, COURSE OF DISEASE, AND TREATMENT OF THE SPONDYLOARTHROPATHIESRheumatic Disease Clinics of North America, 1998
- Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donorsArthritis & Rheumatism, 1998
- Current Guidelines for the Drug Treatment of Ankylosing SpondylitisDrugs, 1998